Dawson L A, Franssen E, Davey P
Department of Radiation Oncology, University of Toronto, Ontario, Canada.
Cancer J Sci Am. 1999 Nov-Dec;5(6):374-9.
The purpose of this study was to determine the impact of a borderline elevated postoperative carcinoembryonic antigen (CEA) on the duration of disease-free survival in patients with rectal cancer treated with postoperative adjuvant radiotherapy and chemotherapy.
A retrospective review was undertaken of 145 patients undergoing curative surgery for rectal adenocarcinoma (American Joint Committee on Cancer stages II and III) and treated with postoperative radiotherapy and chemotherapy from January 1994 to February 1997. Patients with known metastatic disease, with gross residual disease after surgery, or without an available postoperative CEA level before adjuvant therapy were not included. All patients were monitored for a minimum of 1 year or until death. The rates of relapse, disease-free survival and overall survival were estimated according to the Kaplan-Meier method. Univariate analyses for the endpoint time to relapse was carried out for the following potential prognostic factors: age, gender, American Joint Committee on Cancer stage, number of lymph nodes, perineural invasion, capillary-like space invasion, margin status, and postoperative CEA level (< or = 4.0 microg/L vs > 4.0 microg/L). A mulitvariate regression analyses was conducted with the Cox proportional hazards model.
With a median follow-up of 45 months, the disease-free and overall survival rates at 2 years were 78% and 90% respectively. Eight patients were identified who expressed an elevated postoperative CEA (4.1-10.2 microg/L). Two patients had T3N0 tumors; one tumor was T4N0, four tumors were T3N1, and one was T4N1. The median time to first relapse in these eight patients was 26 months, compared with 69 months for the 137 patients with a postoperative CEA in the normal range (0-4.0 microg/L), (log-rank Chi-squared test = 4.92). As determined by a proportional hazards model, an elevated CEA remained an independent predictor (along with number of positive nodes) for early relapse.
Postoperative CEA in patients undergoing curative surgery for rectal cancer provides additional prognostic information in those patients embarking on adjuvant postoperative therapy. An elevated CEA predicts for early relapse and may help define a high-risk subset of patients in whom more aggressive adjuvant therapies should be considered.
本研究旨在确定术后癌胚抗原(CEA)临界升高对接受术后辅助放疗和化疗的直肠癌患者无病生存期的影响。
对1994年1月至1997年2月期间接受根治性手术治疗直肠腺癌(美国癌症联合委员会II期和III期)并接受术后放疗和化疗的145例患者进行回顾性研究。已知有转移性疾病、术后有肉眼可见残留病灶或辅助治疗前无可用术后CEA水平的患者未纳入研究。所有患者至少随访1年或直至死亡。根据Kaplan-Meier方法估计复发率、无病生存率和总生存率。对以下潜在预后因素进行单因素分析,以确定复发终点时间:年龄、性别、美国癌症联合委员会分期、淋巴结数量、神经周围侵犯、毛细血管样间隙侵犯、切缘状态和术后CEA水平(≤4.0μg/L与>4.0μg/L)。使用Cox比例风险模型进行多因素回归分析。
中位随访45个月,2年时无病生存率和总生存率分别为78%和90%。确定有8例患者术后CEA升高(4.1 - 10.2μg/L)。2例患者为T3N0肿瘤;1例为T4N0肿瘤,4例为T3N1肿瘤,1例为T4N1肿瘤。这8例患者首次复发的中位时间为26个月,而术后CEA在正常范围(0 - 4.0μg/L)的137例患者为69个月(对数秩卡方检验 = 4.92)。根据比例风险模型确定,CEA升高仍然是早期复发的独立预测因素(与阳性淋巴结数量一起)。
接受直肠癌根治性手术患者的术后CEA为接受术后辅助治疗的患者提供了额外的预后信息。CEA升高预示早期复发,可能有助于确定应考虑更积极辅助治疗的高危患者亚组。